Cardiology Rx (Repurposed)

Omega-3 (high-dose EPA / icosapent ethyl, prescription)

Grade and summary pending review Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

Prescription high-dose purified EPA. One large trial (REDUCE-IT) showed a 25% reduction in cardiovascular events, and it is FDA-approved (2019). BUT the size of that benefit is contested because the trial's placebo (mineral oil) may have exaggerated it. This is NOT the same as over-the-counter fish oil.

Safety Considerations

Raises the risk of atrial fibrillation (an irregular heart rhythm) and carries a bleeding-risk signal. Prescription product — distinct from OTC fish oil supplements.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing Omega-3 (high-dose EPA / icosapent ethyl, prescription)

No commercial products are currently listed for this molecule.

This evidence profile reflects publicly available research as of October 22, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.